Alirocumab for the treatment of hypercholesterolaemia
G Della Pepa, L Bozzetto, G Annuzzi… - Expert review of …, 2017 - Taylor & Francis
Introduction: Prescription of statins for low-density lipoprotein cholesterol (LDL-C) reduction
is the standard of care in primary and secondary prevention of cardiovascular disease; …
is the standard of care in primary and secondary prevention of cardiovascular disease; …
Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders
S Gupta - Vascular Health and Risk Management, 2016 - Taylor & Francis
The aim of this manuscript is to review available data to evaluate the present status of
proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of …
proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of …
Factors associated with PCSK9 inhibitor initiation among US veterans
CG Derington, LD Colantonio, JS Herrick… - Journal of the …, 2021 - Am Heart Assoc
Background Few adults at high risk for atherosclerotic cardiovascular disease events use a
PCSK9i (proprotein convertase subtilisin/kexin type 9 inhibitor). Methods and Results Using …
PCSK9i (proprotein convertase subtilisin/kexin type 9 inhibitor). Methods and Results Using …
[HTML][HTML] Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center
P Shah, CJ Glueck, V Jetty, N Goldenberg… - Lipids in Health and …, 2016 - Springer
Background PCSK9 inhibitor therapy has been approved by the FDA as an adjunct to diet-
maximal tolerated cholesterol lowering drug therapy for adults with heterozygous familial …
maximal tolerated cholesterol lowering drug therapy for adults with heterozygous familial …
[HTML][HTML] PCSK6 mediates Th1 differentiation and promotes chronic colitis progression and mucosal barrier injury via STAT1
X Mei, H Zhou, Z Song, X Yang, X Liu, J Fei… - Aging (Albany …, 2023 - ncbi.nlm.nih.gov
This study was aimed at investigating the expression and role of proprotein convertase
subtilisin/kexin type (PCSK6) in inflammatory bowel disease (IBD). DSS induced mouse …
subtilisin/kexin type (PCSK6) in inflammatory bowel disease (IBD). DSS induced mouse …
Retargeting the management of hypercholesterolemia–focus on evolocumab
A Colletti, G Derosa, AFG Cicero - Therapeutics and Clinical Risk …, 2016 - Taylor & Francis
Hypercholesterolemia is one of the main risk factors for atherosclerosis and cardiovascular
diseases. The treatment is based on the modification of the diet and lifestyle and if …
diseases. The treatment is based on the modification of the diet and lifestyle and if …
Economic evaluation of the PCSK9 inhibitors in prevention of the cardiovascular diseases
P Shah - Current cardiology reports, 2018 - Springer
Abstract Purpose of Review This review aims to explore and summarize the current literature
on the cardiovascular disease (CVD) healthcare burden and determine the cost …
on the cardiovascular disease (CVD) healthcare burden and determine the cost …
[HTML][HTML] Efficacy, safety, low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to …
P Shah, CJ Glueck, N Goldenberg, S Min… - Lipids in Health and …, 2017 - Springer
Background Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9)
inhibitors, alirocumab (ALI) and evolocumab (EVO) have previously been evaluated through …
inhibitors, alirocumab (ALI) and evolocumab (EVO) have previously been evaluated through …
[HTML][HTML] PCSK9 inhibitors show value for patients and the US health care system
WH Cheng, É Gaudette, DP Goldman - Value in Health, 2017 - Elsevier
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors were approved
by the US Food and Drug Administration (FDA) as cholesterol-lowering therapies for …
by the US Food and Drug Administration (FDA) as cholesterol-lowering therapies for …
[HTML][HTML] Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
J Choi, AM Khan, M Jarmin, N Goldenberg… - Lipids in health and …, 2017 - Springer
Background Efficacy-safety of proprotein convertase subtilisin-kexin type 9 (PCSK9)
inhibitors, alirocumab (ALI) and evolocumab (EVO), have previously been evaluated …
inhibitors, alirocumab (ALI) and evolocumab (EVO), have previously been evaluated …